208 related articles for article (PubMed ID: 26202192)
1. Rifaximin: An Antibiotic with Important Biologic Effects.
DuPont HL
Mini Rev Med Chem; 2015; 16(3):200-5. PubMed ID: 26202192
[TBL] [Abstract][Full Text] [Related]
2. Pharmacokinetic drug evaluation of rifaximin for treatment of diarrhea-predominant irritable bowel syndrome.
Bruzzese E; Pesce M; Sarnelli G; Guarino A
Expert Opin Drug Metab Toxicol; 2018 Jul; 14(7):753-760. PubMed ID: 29897844
[TBL] [Abstract][Full Text] [Related]
3. Rifaximin, a poorly absorbed antibiotic: pharmacology and clinical potential.
Scarpignato C; Pelosini I
Chemotherapy; 2005; 51 Suppl 1():36-66. PubMed ID: 15855748
[TBL] [Abstract][Full Text] [Related]
4. Review article: the antimicrobial effects of rifaximin on the gut microbiota.
DuPont HL
Aliment Pharmacol Ther; 2016 Jan; 43 Suppl 1():3-10. PubMed ID: 26618921
[TBL] [Abstract][Full Text] [Related]
5. Bile acids improve the antimicrobial effect of rifaximin.
Darkoh C; Lichtenberger LM; Ajami N; Dial EJ; Jiang ZD; DuPont HL
Antimicrob Agents Chemother; 2010 Sep; 54(9):3618-24. PubMed ID: 20547807
[TBL] [Abstract][Full Text] [Related]
6. Review article: potential mechanisms of action of rifaximin in the management of irritable bowel syndrome with diarrhoea.
Pimentel M
Aliment Pharmacol Ther; 2016 Jan; 43 Suppl 1():37-49. PubMed ID: 26618924
[TBL] [Abstract][Full Text] [Related]
7. Rifaximin for the treatment of diarrhoea-predominant irritable bowel syndrome.
Laterza L; Ianiro G; Scoleri I; Landi R; Bruno G; Scaldaferri F; Gaetani E; Campanale M; Gasbarrini A
Expert Opin Pharmacother; 2015 Mar; 16(4):607-15. PubMed ID: 25641072
[TBL] [Abstract][Full Text] [Related]
8. Biologic properties and clinical uses of rifaximin.
DuPont HL
Expert Opin Pharmacother; 2011 Feb; 12(2):293-302. PubMed ID: 21226639
[TBL] [Abstract][Full Text] [Related]
9. Rifaximin: a nonabsorbable rifamycin antibiotic for use in nonsystemic gastrointestinal infections.
Gerard L; Garey KW; DuPont HL
Expert Rev Anti Infect Ther; 2005 Apr; 3(2):201-11. PubMed ID: 15918778
[TBL] [Abstract][Full Text] [Related]
10. Introduction: understanding mechanisms of the actions of rifaximin in selected gastrointestinal diseases.
DuPont HL
Aliment Pharmacol Ther; 2016 Jan; 43 Suppl 1():1-2. PubMed ID: 26618920
[TBL] [Abstract][Full Text] [Related]
11. Use of rifaximin in gastrointestinal and liver diseases.
Shayto RH; Abou Mrad R; Sharara AI
World J Gastroenterol; 2016 Aug; 22(29):6638-51. PubMed ID: 27547007
[TBL] [Abstract][Full Text] [Related]
12. Rifaximin pharmacology and clinical implications.
Ojetti V; Lauritano EC; Barbaro F; Migneco A; Ainora ME; Fontana L; Gabrielli M; Gasbarrini A
Expert Opin Drug Metab Toxicol; 2009 Jun; 5(6):675-82. PubMed ID: 19442033
[TBL] [Abstract][Full Text] [Related]
13. Eubiotic properties of rifaximin: Disruption of the traditional concepts in gut microbiota modulation.
Ponziani FR; Zocco MA; D'Aversa F; Pompili M; Gasbarrini A
World J Gastroenterol; 2017 Jul; 23(25):4491-4499. PubMed ID: 28740337
[TBL] [Abstract][Full Text] [Related]
14. The potential for development of clinically relevant microbial resistance to rifaximin-α: a narrative review.
DuPont HL
Clin Microbiol Rev; 2023 Dec; 36(4):e0003923. PubMed ID: 37971270
[TBL] [Abstract][Full Text] [Related]
15. Beneficial effects of Rifaximin in post-infectious irritable bowel syndrome mouse model beyond gut microbiota.
Jin Y; Ren X; Li G; Li Y; Zhang L; Wang H; Qian W; Hou X
J Gastroenterol Hepatol; 2018 Feb; 33(2):443-452. PubMed ID: 28573746
[TBL] [Abstract][Full Text] [Related]
16. The Role of Antibiotics in Gut Microbiota Modulation: The Eubiotic Effects of Rifaximin.
Ponziani FR; Scaldaferri F; Petito V; Paroni Sterbini F; Pecere S; Lopetuso LR; Palladini A; Gerardi V; Masucci L; Pompili M; Cammarota G; Sanguinetti M; Gasbarrini A
Dig Dis; 2016; 34(3):269-78. PubMed ID: 27027301
[TBL] [Abstract][Full Text] [Related]
17. Rifaximin. A review of its antibacterial activity, pharmacokinetic properties and therapeutic potential in conditions mediated by gastrointestinal bacteria.
Gillis JC; Brogden RN
Drugs; 1995 Mar; 49(3):467-84. PubMed ID: 7774516
[TBL] [Abstract][Full Text] [Related]
18. Role of Rifaximin in Inflammatory Bowel Disease Treatment.
Scribano ML
Mini Rev Med Chem; 2015; 16(3):225-9. PubMed ID: 26202194
[TBL] [Abstract][Full Text] [Related]
19. Gut Microbiota Modulation and Mucosal Immunity: Focus on Rifaximin.
Lopetuso LR; Petito V; Scaldaferri F; Gasbarrini A
Mini Rev Med Chem; 2015; 16(3):179-85. PubMed ID: 26643042
[TBL] [Abstract][Full Text] [Related]
20. Rifaximin: a review of its use in the management of traveller's diarrhoea.
Robins GW; Wellington K
Drugs; 2005; 65(12):1697-713. PubMed ID: 16060706
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]